Endometriosis Therapeutics- Pipeline Assessment and Market Forecasts to 2018

Endometriosis Therapeutics- Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Endometriosis Therapeutics- Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global endometriosis therapeutics market and identifies the key trends shaping and driving it. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global endometriosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global endometriosis therapeutics market was valued at $785m in 2010 and will grow at a Compound Annual Growth Rate (CAGR) of 5.9% to reach $1,239m by 2018. This steady growth is primarily attributed to the recently launched product, Visanne (dienogest) and the expected launch of the pipeline product, Elagolix (NBI-56418) in 2015 in the US and Europe. Organizations, such as the Endometriosis Special Interest Group (EndoSIG), through their work are creating awareness about the disease among the general public. This increasing awareness and the resultant higher treatment seeking rates for the disease are also expectecd to contribute to the growth of the market. The current market is underserved due to the lack of specific as well as non-invasive diagnostic techniques, alongside low disease awareness and the poor safety and moderate efficacy profiles of the current marketed therapies. There is a high unmet need which is largely driven by the unavailability of products with adequate efficacy and safety profiles.

Scope

The report provides information on the key drivers and challenges of the endometriosis therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) endometriosis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes of GnRH agonists, GnRH antagonists, Aromatase inhibitors and others.
- Analysis of the current and future competition in the global endometriosis therapeutics market. Key market players covered are Nobelpharma, Novartis AG and Neurocrine Biosciences/Abbott.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the endometriosis therapeutics market.
- Analysis of key recent licensing and partnership agreements in the endometriosis therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global endometriosis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact on the global endometriosis therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global endometriosis therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Endometriosis Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 Referral Pathway
2.7 Treatment and Management Pattern
2.8 Pipeline Report Guidance
3 Endometriosis Therapeutics - Market Characterization
3.1 Overview
3.2 Endometriosis Therapeutics Market Size (2005 - 2010) - Global
3.3 Endometriosis Therapeutics Market Forecast (2010 - 2018) - Global
3.4 Endometriosis Therapeutics Market Size (2005 - 2010) - The US
3.5 Endometriosis Therapeutics Market Forecast (2010 - 2018) - The US
3.6 Endometriosis Therapeutics Market Size (2005 - 2010) - France
3.7 Endometriosis Therapeutics Market Forecast (2010 - 2018) - France
3.8 Endometriosis Therapeutics Market Size (2005 - 2010) - Germany
3.9 Endometriosis Therapeutics Market Forecast (2010-2018) - Germany
3.10 Endometriosis Therapeutics Market Size (2005 - 2010) - Italy
3.11 Endometriosis Therapeutics Market Forecast (2010 - 2018) - Italy
3.12 Endometriosis Therapeutics Market Size (2005 - 2010) - Spain
3.13 Endometriosis Therapeutics Market Forecast (2010 - 2018) - Spain
3.14 Endometriosis Therapeutics Market Size (2005 - 2010) - The UK
3.15 Endometriosis Therapeutics Market Forecast (2010 - 2018) - The UK
3.16 Endometriosis Therapeutics Market Size (2005 - 2010) - Japan
3.17 Endometriosis Therapeutics Market Forecast (2010 - 2018) - Japan
3.18 Drivers and Barriers for the Endometriosis Therapeutics Market
3.18.1 Drivers for the Endometriosis Therapeutics Market
3.18.2 Barriers for the Endometriosis Therapeutics Market
3.19 Opportunity and Unmet Need Analysis
3.19.1 Opportunity and Unmet Need in the Endometriosis Therapeutics Market
3.20 Key Takeaway
4 Endometriosis Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Major Therapies in the Endometriosis Therapeutics Market
4.3.1 Gonadotropin-Releasing Hormone (GnRH) agonists
4.3.2 Progestins
4.3.3 Androgens
4.3.4 Oral Contraceptives
4.3.5 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for Endometriosis
4.4 Key Takeaway
5 Endometriosis Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Endometriosis Therapeutics Pipeline - Pipeline by Phase of Development
5.3.1 Endometriosis Therapeutics - Phase III Clinical Pipeline
5.3.2 Endometriosis Therapeutics - Phase II Pipeline
5.3.3 Endometriosis Therapeutics - Phase I Pipeline
5.3.4 Endometriosis Therapeutics - Preclinical Pipeline
5.4 Technology Trends Analytic Framework
5.5 Endometriosis Therapeutics Market - Pipeline by Mechanism of Action
5.6 Endometriosis Therapeutics - Promising Drugs Under Clinical Development
5.7 Molecule Profile for Promising Drugs Under Clinical Development
5.7.1 NPC-01
5.7.2 Elagolix (NBI-56418)
5.7.3 MPI-676
5.8 Key Takeaway
6 Endometriosis Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/ Country
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Sponsors
6.5 Top Companies Participating in Therapeutics Clinical Trials
7 Endometriosis Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Implications for Future Market Competition
8 Endometriosis Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Nobelpharma Inc.
8.2.2 Novartis AG
8.2.3 Neurocrine Biosciences, Inc.
8.2.4 Repros Therapeutics, Inc
8.2.5 Meditrina Pharmaceuticals, Inc.
8.3 Other Companies in the Endometriosis Therapeutics Market
9 Endometriosis Therapeutics - Licensing and Partnership Deals
10 Endometriosis Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Secondary Research
10.3.2 Forecasting
10.3.3 Primary Research
10.3.4 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Stages Of Endometriosis
Table 2: Risk Factors for Endometriosis
Table 3: Symptoms of Endometriosis
Table 4: Differential Diagnosis of Endometriosis by Symptoms
Table 5: Endometriosis Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Table 6: Endometriosis Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Table 7: Endometriosis Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Table 8: Endometriosis Therapeutics Market, The US, Forecast ($m), 2010 - 2018
Table 9: Endometriosis Therapeutics Market, France, Revenue ($m), 2005 - 2010
Table 10: Endometriosis Therapeutics Market, France, Forecast ($m), 2010 - 2018
Table 11: Endometriosis Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Table 12: Endometriosis Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Table 13: Endometriosis Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Table 14: Endometriosis Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Table 15: Endometriosis Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Table 16: Endometriosis Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Table 17: Endometriosis Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Table 18: Endometriosis Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Table 19: Endometriosis Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Table 20: Endometriosis Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Table 21: Endometriosis Therapeutics - Phase III Clinical Pipeline, 2011
Table 22: Endometriosis Therapeutics - Phase II Clinical Pipeline, 2011
Table 23: Endometriosis Therapeutics - Phase I Clinical Pipeline, 2011
Table 24: Endometriosis Therapeutics - Preclinical Pipeline, 2011
Table 25: Endometriosis Therapeutics - Promising Drugs Under Clinical Development, 2011
Table 26: Endometriosis Therapeutics Market, Clinical Trials by Country, 2011
Table 27: Endometriosis Therapeutics Market, Clinical Trials by Phase, 2011
Table 28: Endometriosis Therapeutics Market, Clinical Trials by Trial Status, 2011
Table 29: Endometriosis Therapeutics Market - Clinical Trials by Prominent Sponsors, 2011
Table 30: Endometriosis Therapeutics Market, Global, Clinical Trials by Top Companies, 2011
Table 31: Nobelpharma - Endometriosis Pipeline Products, 2011
Table 32: Novartis AG - Endometriosis Pipeline Products, 2011
Table 33: Neurocrine Biosciences, Inc. - Endometriosis Pipeline Products, 2011
Table 34: Repros Therapeutics Inc. - Endometriosis Pipeline Products, 2011
Table 35: Meditrina Pharmaceuticals, Inc. - Endometriosis Pipeline Products, 2011
Table 36: Other Companies in the Endometriosis Therapeutics Market, 2011
Table 37: Endometriosis Therapeutics Market, Global, Deals, 2009-2010

1.2 List of Figures
Figure 1: Female Reproductive Tract with Endometriosis
Figure 2: Basic Anatomy Of Retrograde Menstruation
Figure 3: Theories Supporting Etiology
Figure 4: Referral Pathway for Endometriosis
Figure 5: Diagnosis and Treatment Algorithm Of Endometriosis
Figure 6: Endometriosis Treatment Options
Figure 7: Treatment Of Patients with Endometriosis
Figure 8: Surgical vs. Medical Treatment Of Endometriosis
Figure 9: Endometriosis Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Figure 10: Endometriosis Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Figure 11: Endometriosis Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Figure 12: Endometriosis Therapeutics Market, The US, Forecast ($m), 2010 - 2018
Figure 13: Endometriosis Therapeutics Market, France, Revenue ($m), 2005 - 2010
Figure 14: Endometriosis Therapeutics Market, France, Forecast ($m), 2010 - 2018
Figure 15: Endometriosis Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Figure 16: Endometriosis Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Figure 17: Endometriosis Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Figure 18: Endometriosis Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Figure 19: Endometriosis Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Figure 20: Endometriosis Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Figure 21: Endometriosis Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Figure 22: Endometriosis Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Figure 23: Endometriosis Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Figure 24: Endometriosis Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Figure 25: Opportunity and Unmet Need in the Endometriosis Therapeutics Market, 2010
Figure 26: Strategic Competitor Assessment of the Major Marketed Products for Endometriosis, 2011
Figure 27: Clinical Experience with Visanne at a Glance
Figure 28: Clinical Study Details - Visanne
Figure 29: Clinical Study Details - Visanne
Figure 30: Clinical Study Details - Visanne
Figure 31: Endometriosis Therapeutics - Pipeline by Phase of Development, 2011
Figure 32: Technology Trends Analytic Framework of the Endometriosis Therapeutics Pipeline, 2011
Figure 33: Technology Trends Analytic Framework of the Endometriosis Therapeutics Pipeline- Description, 2011
Figure 34: Endometriosis Therapeutics Market - Pipeline by Mechanism Of Action, 2011
Figure 35: Elagolix Product Attributes
Figure 36: Elagolix Expected Advantages vs. Approved Agents
Figure 37: Endometriosis Therapeutics Market, Clinical Trials by Country, 2011
Figure 38: Endometriosis Therapeutics Market - Clinical Pipeline by Phase, 2011
Figure 39: Endometriosis Therapeutics Market - Clinical Trials by Trial Status, 2011
Figure 40: Endometriosis Therapeutics Market - Clinical Trials by Overall Sponsors, 2011
Figure 41: Endometriosis Therapeutics Market - Clinical Trials by Prominent Sponsors, 2011
Figure 42: Endometriosis Therapeutics Market, Global, Clinical Trials by Top Companies, 2011
Figure 43: Endometriosis Therapeutics Market, Drivers and Barriers, 2011
Figure 44: Implications for Future Market Competition in the Endometriosis Therapeutics Market, 2011
Figure 45: Endometriosis Therapeutics Market, Pipeline by Company, 2011

GlobalData, the industry analysis specialist, has released its new report, “Endometriosis Therapeutics- Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global endometriosis therapeutics market and identifies the key trends shaping and driving it. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global endometriosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Endometriosis Therapeutics Market is forecast to Show Steady Growth until 2018

GlobalData estimates that the global endometriosis therapeutics market was valued at $785m in 2010 and will grow at a Compound Annual Growth Rate (CAGR) of 5.9% to reach $1,239m by 2018. This steady growth is primarily attributed to the recently launched product, Visanne (dienogest), and the expected launch of the pipeline product, Elagolix (NBI-56418), in 2015 in the US and Europe. Organizations such as the Endometriosis Special Interest Group (EndoSIG), through their work are increasing awareness about the disease among the general public. This increasing awareness and the resultant higher treatment seeking rates for the disease are also expectecd to contribute to the growth of the market. The current market is underserved due to the lack of specific as well as non-invasive diagnostic techniques, alongside low disease awareness and the poor safety and moderate efficacy profiles of the current marketed therapies. There is a high unmet need which is largely driven by the unavailability of products with adequate efficacy and safety profiles.

Endometriosis Therapeutics Market, Global, Forecast ($m), 2005 - 2018

Source: GlobalData, Neurocrine Biosciences company website; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of health (NIH), The US; Endometriosis Research Center International, The US; Bayer company website

Current Competition in the Endometriosis Therapeutics Market is Weak

The current competition in the endometriosis therapeutics market is weak. The global market currently has hormonal therapy as the mainstay for the treatment for endometriosis. At present, the treatment options are limited to gonadotropin-releasing hormone (GnRH) agonists, progestins, and androgens, whose long term use is associated with undesirable side effects such as chronic pelvic pain, infertility, edema, changes in weight, migraines, depression, mood swings, nausea, hot flashes, breast enlargement/tenderness, changes in cervical erosion and cervical secretions, breakthrough bleeding and amenorrhea. All other drugs, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and oral contraceptives (OCs) are prescribed off-label by physicians. The currently available pharmacological and surgical treatment options primarily target short term symptomatic relief with none of them capable of treating the progression of the disease. Thus, the endometriosis therapeutics market has a high unmet need for therapies with higher efficacy and better and long-term safety as well as for disease modifying drugs. The market holds significant commercial potential for such novel therapies.

Nobelpharma Inc.
Novartis AG
Neurocrine Biosciences, Inc.
Repros Therapeutics, Inc
Meditrina Pharmaceuticals, Inc.

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.